37794975|t|Ellagic acid effects on disease severity, levels of cytokines and T-bet, RORgammat, and GATA3 genes expression in multiple sclerosis patients: a multicentral-triple blind randomized clinical trial.
37794975|a|Background: Multiple sclerosis (MS) is a chronic autoimmune disease. Ellagic acid is a natural polyphenol and affects the fate of neurons through its anti-inflammatory and antioxidant properties. The present study aimed to investigate ellagic acid effects on disease severity, the expression of involved genes in the pathogenesis of MS, and the levels of related cytokines. Methods: The present study was a triple-blind clinical trial. Eligible patients were randomly assigned to two groups: Ellagic acid (25 subjects) for 12 weeks, receiving 180 mg of Ellagic acid (Axenic, Australia) and the control group (25 subjects) receiving a placebo, before the main meals. Before and after the study, the data including general information, foods intake, physical activity, anthropometric data, expanded disability status scale (EDSS), general health questionnaire (GHQ) and pain rating index (PRI), fatigue severity scale (FSS) were assessed, as well as serum levels of interferon-gamma (IFNgamma), interleukin-17 (IL-17), interleukin-4 (IL-4) and transforming growth factor-beta (TGF-beta), nitric-oxide (NO) using enzyme-linked immunoassay (ELISA) method and expression of T-box transcription factor (Tbet), GATA Binding Protein 3 (GATA3), retinoic acid-related orphan receptor-gammat (RORgammat) and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes were determined using Real-Time Quantitative Reverse Transcription PCR (RT-qPCR) method. Findings: Ellagic acid supplementation led to a reduction in IFNgamma, IL-17, NO and increased IL-4 in the ellagic acid group, however in the placebo group no such changes were observed (-24.52 +- 3.79 vs. -0.05 +- 0.02, p < 0.01; -5.37 +- 0.92 vs. 2.03 +- 1.03, p < 0.01; -18.03 +- 1.02 vs. -0.06 +- 0.05, p < 0.01, 14.69 +- 0.47 vs. -0.09 +- 0.14, p < 0.01, respectively). Ellagic acid supplementation had no effect on TGF-beta in any of the study groups (p > 0.05). Also, the Tbet and RORgammat genes expression decreased, and the GATA3 gene expression in the group receiving ellagic acid compared to control group significantly increased (0.52 +- 0.29 vs. 1.51 +- 0.18, p < 0.01, 0.49 +- 0.18 vs. 1.38 +- 0.14, p < 0.01, 1.71 +- 0.39 vs. 0.27 +- 0.10, p < 0.01). Also, ellagic acid supplementation led to significant decrease in EDSS, FSS and GHQ scores (p < 0.05), and no significant changes observed in PRI score (p > 0.05). Conclusion: Ellagic acid supplementation can improve the health status of MS patients by reduction of the inflammatory cytokines and Tbet and RORgammat gene expression, and increment of anti-inflammatory cytokines and GATA3 gene expression.Clinical trial registration: (https://en.irct.ir/trial/53020), IRCT20120415009472N22.
37794975	0	12	Ellagic acid	Chemical	MESH:D004610
37794975	66	71	T-bet	Gene	30009
37794975	88	93	GATA3	Gene	2625
37794975	114	132	multiple sclerosis	Disease	MESH:D009103
37794975	210	228	Multiple sclerosis	Disease	MESH:D009103
37794975	230	232	MS	Disease	MESH:D009103
37794975	247	265	autoimmune disease	Disease	MESH:D001327
37794975	267	279	Ellagic acid	Chemical	MESH:D004610
37794975	293	303	polyphenol	Chemical	MESH:D059808
37794975	353	365	inflammatory	Disease	MESH:D007249
37794975	433	445	ellagic acid	Chemical	MESH:D004610
37794975	531	533	MS	Disease	MESH:D009103
37794975	690	702	Ellagic acid	Chemical	MESH:D004610
37794975	751	763	Ellagic acid	Chemical	MESH:D004610
37794975	1066	1070	pain	Disease	MESH:D010146
37794975	1091	1098	fatigue	Disease	MESH:D005221
37794975	1162	1178	interferon-gamma	Gene	3458
37794975	1180	1188	IFNgamma	Gene	3458
37794975	1191	1205	interleukin-17	Gene	3605
37794975	1207	1212	IL-17	Gene	3605
37794975	1215	1228	interleukin-4	Gene	3565
37794975	1230	1234	IL-4	Gene	3565
37794975	1240	1271	transforming growth factor-beta	Gene	7040
37794975	1273	1281	TGF-beta	Gene	7040
37794975	1284	1296	nitric-oxide	Chemical	MESH:D009569
37794975	1395	1399	Tbet	Gene	30009
37794975	1402	1424	GATA Binding Protein 3	Gene	2625
37794975	1426	1431	GATA3	Gene	2625
37794975	1495	1535	Glyceraldehyde-3-phosphate dehydrogenase	Gene	2597
37794975	1537	1542	GAPDH	Gene	2597
37794975	1649	1661	Ellagic acid	Chemical	MESH:D004610
37794975	1700	1708	IFNgamma	Gene	3458
37794975	1710	1715	IL-17	Gene	3605
37794975	1734	1738	IL-4	Gene	3565
37794975	1746	1758	ellagic acid	Chemical	MESH:D004610
37794975	2014	2026	Ellagic acid	Chemical	MESH:D004610
37794975	2060	2068	TGF-beta	Gene	7040
37794975	2118	2122	Tbet	Gene	30009
37794975	2173	2178	GATA3	Gene	2625
37794975	2218	2230	ellagic acid	Chemical	MESH:D004610
37794975	2412	2424	ellagic acid	Chemical	MESH:D004610
37794975	2582	2594	Ellagic acid	Chemical	MESH:D004610
37794975	2644	2646	MS	Disease	MESH:D009103
37794975	2676	2688	inflammatory	Disease	MESH:D007249
37794975	2703	2707	Tbet	Gene	30009
37794975	2761	2773	inflammatory	Disease	MESH:D007249
37794975	2788	2793	GATA3	Gene	2625
37794975	Association	MESH:D009103	2625
37794975	Negative_Correlation	MESH:D004610	3605
37794975	Negative_Correlation	MESH:D004610	MESH:D005221
37794975	Negative_Correlation	MESH:D004610	MESH:D007249
37794975	Association	MESH:D004610	2625
37794975	Negative_Correlation	MESH:D004610	3458
37794975	Negative_Correlation	MESH:D004610	7040
37794975	Negative_Correlation	MESH:D004610	MESH:D009569
37794975	Negative_Correlation	MESH:D004610	MESH:D009103
37794975	Association	MESH:D004610	30009
37794975	Positive_Correlation	MESH:D004610	3565

